Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Change in Acquisitions & Divestments (2020 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $48.5 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Change in Acquisitions & Divestments fell 33.71% year-over-year to $48.5 million, compared with a TTM value of $182.8 million through Dec 2021, up 101.07%, and an annual FY2024 reading of $139.8 million, up 78.77% over the prior year.
  • Change in Acquisitions & Divestments was $48.5 million for Q4 2021 at Black Diamond Therapeutics, up from $39.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $73.2 million in Q4 2020 and bottomed at $17.8 million in Q3 2020.